ABSTRACT C-Myc overexpression is a common finding in pancreatic cancer and predicts
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high
mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by …

Importance KRASmutations are common in pancreatic cancer, but directly targeting the
KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and …

Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal
adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK …

Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies.
Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of …

Purpose: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and
PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has …

Pancreatic cancer belongs to the incurable family of solid cancers. Despite of a recent better
understanding its molecular biology, and an increased number of clinical trials, there is still a …

KRAS is activated by mutation in the vast majority of cases of pancreatic cancer;
unfortunately, therapeutic attempts to inhibit KRAS directly have been unsuccessful. Our …

The Ras subfamily of small GTPases is mutated in∼ 30% of human cancers and represents
compelling yet challenging anticancer drug targets owing to their flat protein surface. We …